Metabolic and proteomic landscapes of DMG and DHG: Navigating uncharted paths for therapeutic discovery

DMG-K27M and DHG-H3G34 are rare cancers and the number of patient samples in our possession is limited. The CBTN request is crucial as it provides an opportunity to access a substantial number of well-curated DMG-H3K27 and DHG-H3G34 specimens, allowing us to form a representative cohort for our metabolomic profiling. By specifically targeting this rare and less-studied pediatric glioma through CBTN, we aim to contribute valuable insights into the metabolic and proteomic alterations unique to these DMGs and DHGs.